Analysts See $-0.44 EPS for Flex Pharma, Inc. (FLKS)

July 27, 2018 - By Jack Shaw

Flex Pharma, Inc. (NASDAQ:FLKS) Logo

Analysts expect Flex Pharma, Inc. (NASDAQ:FLKS) to report $-0.44 EPS on August, 1.They anticipate $0.07 EPS change or 13.73 % from last quarter’s $-0.51 EPS. After having $-0.46 EPS previously, Flex Pharma, Inc.’s analysts see -4.35 % EPS growth. The stock increased 2.38% or $0.0195 during the last trading session, reaching $0.8396. About 41,053 shares traded. Flex Pharma, Inc. (NASDAQ:FLKS) has risen 16.07% since July 27, 2017 and is uptrending. It has outperformed by 3.50% the S&P500.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Coverage

Among 3 analysts covering Flex Pharma (NASDAQ:FLKS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Flex Pharma has $40.0 highest and $6.0 lowest target. $19.67’s average target is 2242.78% above currents $0.8396 stock price. Flex Pharma had 4 analyst reports since February 13, 2018 according to SRatingsIntel. Jefferies maintained Flex Pharma, Inc. (NASDAQ:FLKS) on Friday, April 6 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, June 13 by Ladenburg Thalmann. The firm has “Buy” rating by Jefferies given on Tuesday, February 13. H.C. Wainwright maintained the shares of FLKS in report on Thursday, March 8 with “Buy” rating.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $15.12 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

More notable recent Flex Pharma, Inc. (NASDAQ:FLKS) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT – FLR FLKS FPI MD MRCY REVG: The Law Offices of Vincent Wong Reminds Investors of …” on July 19, 2018, also Globenewswire.com with their article: “CLASS ACTION UPDATE for MRCY and FLKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of …” published on July 15, 2018, Globenewswire.com published: “UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FLKS …” on July 18, 2018. More interesting news about Flex Pharma, Inc. (NASDAQ:FLKS) were released by: Globenewswire.com and their article: “CLASS ACTION DEADLINE MONDAY for FLR, UNM and FLKS: Levi & Korsinsky, LLP Reminds Investors of Class …” published on July 19, 2018 as well as Globenewswire.com‘s news article titled: “The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COOL, HAIR, SBGL, GOGO and …” with publication date: July 26, 2018.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.